Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on treating cancer with Veyonda®, its lead drug candidate.

Veyonda® is a dual-acting oncotoxic and immuno-oncology drug designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapy, radiotherapy and immuno-oncology drugs. The drug acts by harnessing the body’s immune system to inflict damage oncancer cells in the body and has shown promise in treating a broad spectrum of cancers.

Noxopharm also has an active research and development (R&D) program for additional drug candidates and is the major shareholder of US biotechnology company Nyrada Inc. (ASX:NYR). 

Latest Media Releases

Noxopharm IONIC Immuno-Oncology Trial Commences

19/03/2021 09:43:00

Highlights: Ethics Approval received for IONIC-1 clinical trial, with trial to commence immediately in Australian hospitals IONIC-1 to test combination of Veyonda® with blockbuster Bristol…

NOXCOVID Trial Advances to Final Stage

08/03/2021 10:23:00

Positive review of hospitalized COVID-19 patients triggers approval to move from Part 1 to Part 2 of the trial Top dose of 1800 mg Veyonda daily to be used in final patient cohort Tests on blood …

Latest News